Research Topics
| Jordana K SchmierSummaryAffiliation: Exponent Inc Country: USA Publications
| Collaborators
|
Detail Information
Publications
The burden of age-related macular degenerationJordana K Schmier
Exponent, Alexandria, Virginia, USA
Pharmacoeconomics 24:319-34. 2006..Further research is needed to integrate the information on various components of AMD-related costs into a comprehensive burden of illness estimate and to evaluate basic utility assumptions in existing models...- Evaluation of Medicare costs of endophthalmitis among patients after cataract surgeryJordana K Schmier
Exponent, Inc, Alexandria, Virginia 22314, USA
Ophthalmology 114:1094-9. 2007..However, little is known about the cost of treatment. The objective of this study was to estimate the direct medical cost of treatment for endophthalmitis in the United States... 
Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucomaJordana K Schmier
Exponent Inc, Alexandria, VA 22314, USA
Clin Drug Investig 32:835-42. 2012..Topical β-blockers are commonly prescribed for primary open-angle glaucoma. Existing research is limited regarding respiratory or cardiovascular events that may result from using these topical β-blockers...- Patterns and costs associated with progression of age-related macular degenerationJordana K Schmier
Exponent, Inc, Alexandria, Virginia, USA
Am J Ophthalmol 154:675-681.e1. 2012..To evaluate patterns of disease progression among individuals with age-related macular degeneration (AMD) and to compare costs over time... - The impact of inadequately controlled asthma in urban children on quality of life and productivityJordana K Schmier
Exponent, Alexandria, Virginia 22314, USA
Ann Allergy Asthma Immunol 98:245-51. 2007..The burden of inadequately controlled pediatric asthma on education and other daily activities is not well described... - Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progressionJordana K Schmier
Exponent Inc, Alexandria, VA 22314, USA
Curr Med Res Opin 22:1737-43. 2006..In addition, visual functioning is known to affect medical costs. The objective of this study was to project visual field deficit progression and subsequent costs based on clinical trial data... - Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD)Jordana K Schmier
Exponent Inc, Alexandria, Virginia 22314, USA
Disabil Rehabil 28:1331-7. 2006..To assess the patient-reported use of services, supplements, and devices among individuals with age-related macular degeneration (AMD) and evaluate the impact of visual impairment level on this use... - Medicare expenditures associated with diabetes and diabetic retinopathyJordana K Schmier
Exponent, Inc, Alexandria, Virginia, USA
Retina 29:199-206. 2009..To estimate the expenditures for diabetic retinopathy in the United States by Medicare... - Impact of visual impairment on use of caregiving by individuals with age-related macular degenerationJordana K Schmier
Exponent Inc, Alexandria, VA, USA
Retina 26:1056-62. 2006..To assess the patient-reported use of caregiving among individuals with age-related macular degeneration (AMD) and evaluate the impact of visual impairment level on this use... - Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspectiveJordana K Schmier
Exponent Inc, Alexandria, VA 22314, USA
Curr Med Res Opin 23:2867-75. 2007..To evaluate costs associated with prostaglandin analogs among newly-diagnosed glaucoma patients in a managed-care population... - Evaluation of costs for cystoid macular edema among patients after cataract surgeryJordana K Schmier
Exponent Inc, 1800 Diagonal Road, Alexandria, VA 22314, USA
Retina 27:621-8. 2007..Little is known about the costs of cystoid macular edema (CME), an important complication associated with cataract surgery. The purpose of this analysis was to estimate the cost of treatment for CME in the United States... - Impact of visual impairment on service and device use by individuals with diabetic retinopathyJordana K Schmier
Exponent, Alexandria, VA, USA
Disabil Rehabil 31:659-65. 2009..This study was performed to assess the use of devices and caregiving among individuals with diabetic retinopathy and to evaluate the impact of visual acuity on use... - The economic implications of glaucoma: a literature reviewJordana K Schmier
Exponent, Alexandria, Virginia 22314, USA
Pharmacoeconomics 25:287-308. 2007..As new screening technologies for early detection of individuals at elevated risk of glaucoma are now in use, more complete estimates of the cost of glaucoma are critical for issues of resource allocation and health policy... - Validation of the Daily Living Tasks Dependent on Vision (DLTV) questionnaire in a U.S. population with age-related macular degenerationJordana K Schmier
Exponent, Inc, Alexandria, VA 22314, USA
Ophthalmic Epidemiol 13:137-43. 2006..This study evaluated the psychometric properties of the DLTV using patient-reported rates of use of services and devices in an outpatient population... - First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008Jordana K Schmier
Managing Scientist, Exponent Inc, Alexandria, VA, USA
Curr Med Res Opin 26:2769-77. 2010..The objective of this analysis was to estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population... - Trends in annual medicare expenditures for glaucoma surgical procedures from 1997 to 2006Jordana K Schmier
Exponent, Inc, 1800 Diagonal Rd, Ste 300, Alexandria, VA 22314, USA
Arch Ophthalmol 127:900-5. 2009..To identify payments and changes in payments for glaucoma surgical procedures among Medicare beneficiaries in the United States and to evaluate trends in costs based on the types of procedures being performed... - The impact of climate change and aeroallergens on children's healthJordana K Schmier
Exponent, Inc, Alexandria, Virginia 22314, USA
Allergy Asthma Proc 30:229-37. 2009..Strategies to reduce the impacts should be developed and implemented now... 
Single food focus dietary guidance: lessons learned from an economic analysis of egg consumptionJordana K Schmier
Exponent, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, USA
Cost Eff Resour Alloc 7:7. 2009..As newer data become available, the model should be updated...- First-year treatment patterns among new initiators of topical prostaglandin analogsJordana K Schmier
Exponent Inc, 1800 Diagonal Road, Alexandria, VA 22314, USA
Curr Med Res Opin 25:851-8. 2009..To evaluate treatment patterns and costs among new initiators of topical prostaglandin analogs in a managed-care population... - Practical applications of usability theory to electronic data collection for clinical trialsJordana K Schmier
Exponent, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, United States
Contemp Clin Trials 26:376-85. 2005..Lessons learned from usability testing in the unique setting of the clinical trial can be applied to other projects to decrease costs, enhance the quality of the data, and minimize time to analysis... - Cost of obesity in the workplaceJordana K Schmier
Exponent Inc, Alexandria, Virginia, USA
Scand J Work Environ Health 32:5-11. 2006..Obesity is an important driver of costs in the workplace. These findings quantify the costs and can help employers consider whether to introduce workplace interventions or provide coverage for weight loss programs... - Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidenceJordana K Schmier
Exponent Inc, Alexandria, Virginia 22314, USA
Drugs Aging 22:717-29. 2005.... - Resource utilization and costs of age-related macular degenerationMichael T Halpern
Exponent Inc, Alexandria, VA 22314, USA
Health Care Financ Rev 27:37-47. 2006..Costs among patients with wet disease increased yearly at rates exceeding inflation, possibly due in part to increased rates of treatment with photodynamic therapy among these individuals and the aging of the population... - Impacts of a smoking cessation benefit among employed populationsMichael T Halpern
Exponent, Alexandria, Virginia, USA
J Occup Environ Med 49:11-21. 2007..The objective of this study was to project the health and economic impacts of providing a workplace smoking cessation benefit... - Costs and outcomes of extended-release vs. immediate-release clarithromycin for lower respiratory tract infectionsMichael T Halpern
Exponent, Health Sciences Group, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, USA
COPD 2:217-23. 2005..Results indicate that clarithromycin extended-release is cost-saving compared with immediate-release for LRTI... - The quality of life impact of acute exacerbations of chronic bronchitis (AECB): a literature reviewJordana K Schmier
Exponent, Alexandria, VA 22314, USA
Qual Life Res 14:329-47. 2005..Health-related quality of life (HRQL) is impaired in patients with COPD, but little is known about the direct effect of exacerbations on HRQL... - Allergic rhinitis: a potential cause of increased asthma medication use, costs, and morbidityMichael T Halpern
Exponent Inc, Alexandria, Virginia, USA
J Asthma 41:117-26. 2004..Physicians should assess asthma patients for symptoms of allergic rhinitis to improve asthma treatment... - The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature reviewMichael T Halpern
Exponent Inc, Alexandria, VA 22314, USA
J Manag Care Pharm 9:353-9. 2003..Medical resource use associated with AECB can have a substantial economic impact on the patients, health care system, and society overall... - The cost-effectiveness of omega-3 supplements for prevention of secondary coronary eventsJordana K Schmier
Exponent, Alexandria, VA 22314, USA
Manag Care 15:43-50. 2006..Despite model limitations, omega-3 supplementation should be considered an important and cost-effective option for prevention of secondary cardiovascular events... - Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysisMichael T Halpern
Exponent, Alexandria, Virginia, USA
Ann Allergy Asthma Immunol 92:201-7; quiz 207-8, 267. 2004..The impact of long-term inhaled corticosteroid (ICS) therapy on bone mineral density (BMD) is poorly understood... - First-year treatment costs among new initiators of topical prostaglandin analogsJordana K Schmier
Exponent Inc, Alexandria, VA, USA
Clin Ophthalmol 3:637-44. 2009..To estimate first-year costs among new initiators of topical prostaglandin analogs in a managed care population... - Meta-analysis of bacterial resistance to macrolidesMichael T Halpern
Exponent, Inc, 1800 Diagonal Road, Suite 300, Alexandria, VA 22314, USA
J Antimicrob Chemother 55:748-57. 2005..This meta-analysis systematically evaluated resistance of Streptococcus pneumoniae and Streptococcus pyogenes to macrolide antibiotics among patients with community-acquired respiratory tract infections... - Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogsJordana K Schmier
Exponent, Alexandria, VI, USA
Clin Ophthalmol 4:1137-43. 2010..To determine treatment patterns and costs over a two-year period among new initiators of topical prostaglandin analogs in a managed care population by retrospective cohort analysis of an insurance claims database... - Economic burden of periprosthetic joint infection in the United StatesSteven M Kurtz
Exponent, Inc, Philadelphia, Pennsylvania Drexel University, Philadelphia, Pennsylvania, USA
J Arthroplasty 27:61-5.e1. 2012..62 billion by 2020. As the demand for joint arthroplasty is expected to increase substantially over the coming decade, so too will the economic burden of prosthetic infections... - Mortality, cost, and health outcomes of total knee arthroplasty in medicare patientsScott T Lovald
Exponent, Inc, Menlo Park, CA 94025, USA
J Arthroplasty 28:449-54. 2013..9% at 7years (HR=0.93, P<0.001). The results demonstrate the patients in the TKA cohort as having a lower probability of heart failure and mortality, at a total incremental cost of $19,843... - First-year treatment costs among new initiators of topical prostaglandin analogs: pooled resultsJordana K Schmier
Managing Scientist, Exponent Inc, Alexandria, VA, USA
Clin Ophthalmol 4:437-45. 2010..To estimate first-year treatment costs among new initiators of topical prostaglandin analogs in a managed care population... - Characteristics of respondents with glaucoma and dry eye in a national panel surveyJordana K Schmier
Exponent Inc, Alexandria, VA, USA
Clin Ophthalmol 3:645-50. 2009..There is an increasing body of evidence strongly suggesting that glaucoma medications may contribute to ocular surface disease and development of dry eye... - A stitch in time: improving public health early warning systems for extreme weather eventsKristie L Ebi
Exponent, Inc, Alexandria, VA 22314, USA
Epidemiol Rev 27:115-21. 2005 - The cost effectiveness of varenicline for smoking cessationMichael T Halpern
Department of Health Policy and Management, Emory University, Atlanta, Georgia 30322, USA
Manag Care Interface 20:18-25. 2007..Employers often experience additional savings from decreased absenteeism and increased productivity, with combined savings in health care plus workplace costs associated with varenicline use of $165 to $457 per smoker over two years... - Cost effectiveness of treatment of Parkinson's disease with entacapone in the United StatesCynthia S Palmer
MEDTAP International, Bethesda, Maryland, USA
Pharmacoeconomics 20:617-28. 2002..Results of this modelling exercise suggest that therapy with entacapone may be cost effective when compared with standard treatment for PD...